TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xbrane Biopharma AB ( (SE:XBRANE) ) has provided an update.
Xbrane Biopharma AB held an extra general meeting where it approved a directed issue of shares, deviating from shareholders’ preferential rights. This strategic move is intended to strengthen the company’s financial position, attract reputable long-term shareholders, and support its ongoing development and commercialization of biosimilars. The decision to opt for a directed issue over a rights issue is based on factors such as time efficiency, cost-effectiveness, and minimizing market risk exposure.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a biopharmaceutical company focused on developing and commercializing biosimilars. The company operates in the healthcare industry, aiming to provide cost-effective alternatives to existing biologic drugs.
Average Trading Volume: 15,242,770
Current Market Cap: SEK381.8M
For a thorough assessment of XBRANE stock, go to TipRanks’ Stock Analysis page.